CRL
Charles River Laboratories International, Inc.
Stock
$290.19+3.36 (+1.17%)Close Oct 2, 2026
Cash flow statement
| Line | Last 12 months | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $582M | $738M | $735M | $684M | $620M | $761M | $547M | $481M | $441M | $318M | $317M | — | — | — | — | — | — | — | — |
| Capital expenditures | $212M | $219M | $233M | $319M | $325M | $229M | $167M | $141M | $140M | $82M | $55M | $63M | $57M | $39M | $48M | $49M | $43M | $80M | $199M |
| Free cash flow | $371M | $518M | $502M | $365M | $295M | $532M | $380M | $340M | $301M | $236M | $262M | — | — | — | — | — | — | — | — |
| Stock-based compensation | $83M | $71M | $70M | $72M | $74M | $71M | $56M | $57M | $47M | $44M | $44M | $40M | $31M | $25M | $22M | $22M | $26M | $24M | $24M |
| Buybacks | $324M | $361M | $119M | $24M | $39M | $41M | $24M | $18M | $14M | $107M | $12M | $117M | $122M | $166M | $64M | $284M | $357M | $46M | $115M |
| Free cash flow margin | 9.3% | 12.9% | 12.4% | 8.8% | 7.4% | 15.0% | 13.0% | 13.0% | 13.3% | 12.7% | 15.6% | — | — | — | — | — | — | — | — |